Biblio Discovery — Demo Discovery Service

9 results for "Siegbert Rossol"

Showing 1–9 · 0.61 seconds · RSS

  1. Journal Article

    Current management of intramural duodenal hematoma in alcohol induced pancreatitis

    Florian Bert; Thomas Jun; Siegbert Rossol

    Gastroenterology Insights, Vol. 8 No. 1 · 2017 · English · DOAJ

    Intramural duodenal hematomas (IDH) have been rarely associated with pancreatic diseases. Conservative treatment is recommended, but course of disease can be life threatening, serious complications may occur (i.e. duodenal perforation) with imperative surgery. The management of diagnostic and…

  2. Journal Article Full text

    Cost-Effectiveness of Treating Hepatitis C with Sofosbuvir/Ledipasvir in Germany.

    Jona T Stahmeyer; Siegbert Rossol; Sebastian Liersch et al.

    PLoS ONE, Vol. 12 No. 1 · 2017 · English · DOAJ Scopus

    BackgroundInfections with the hepatitis C virus (HCV) are a global public health problem. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. Newly introduced direct acting antivirals, especially interferon-free regimens, have improved rates of sustained…

    Also available at: PLOS

  3. Journal Article Full text

    Is there a place for sigmoidoscopy in colorectal cancer screening? A systematic review and critical appraisal of cost-effectiveness models

    Leonie Diedrich; Melanie Brinkmann; Maren Dreier et al.

    PLOS ONE, Vol. 18 No. 8 · 2023 · English · PLOS Scopus

    Introduction: Screening for colorectal cancer (CRC) is effective in reducing both incidence and mortality. Colonoscopy and stool tests are most frequently used for this purpose. Sigmoidoscopy is an alternative screening measure with a strong evidence base. Due to its distinct characteristics, it…

  4. Journal Article Full text

    Lifestyle interventions for patients with non-alcoholic steato-hepatitis–Design, rationale and protocol of the study “target group-specific optimisation of lifestyle interventions for behavior change in non-alcoholic steato-hepatitis (OPTI-NASH)”

    Kathrin Krüger; Carina Oedingen; Achim Kautz et al.

    PLOS ONE, Vol. 18 No. 7 · 2023 · English · PLOS Scopus

    Background: Non-alcoholic steato-hepatitis (NASH) is the inflammatory, progressive form of non-alcoholic fatty liver disease (NAFLD). A delayed diagnose interval is typical for the majority of the patients because of the asymptomatic natural course. However, serious sequelae may develop such as…

  5. Journal Article

    Elimination of hepatitis C virus in Germany: modelling the cost-effectiveness of HCV screening strategies

    Christian Krauth; Siegbert Rossol; Gustaf Ortsäter et al.

    BMC Infectious Diseases, Vol. 19 No. 1 · 2019 · English · DOAJ Scopus

    Abstract Background Chronic hepatitis C is a major public health burden. With new interferon-free direct-acting agents (showing sustained viral response rates of more than 98%), elimination of HCV seems feasible for the first time. However, as HCV infection often remains undiagnosed, screening is…

  6. Journal Article

    Cost-effectiveness of Triple Therapy with Telaprevir for Chronic Hepatitis C Virus Patients in Germany

    Jona T. Stahmeyer; Svenja Schauer; Siegbert Rossol et al.

    Journal of Health Economics and Outcomes Research, Vol. 1 No. 3 · 2013 · English · DOAJ Scopus

    # Background About 400,000-500,000 people are infected with hepatitis C in Germany. Long-term consequences are the development of liver cirrhosis and hepatocellular carcinoma. The introduction of first generation protease inhibitors has significantly improved the treatment of hepatitis C genotype 1…

  7. Journal Article Full text

    Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors – Results from the PAN Study

    Jona T. Stahmeyer; Siegbert Rossol; Florian Bert et al.

    PLOS ONE, Vol. 11 No. 7 · 2016 · English · PLOS Scopus

    1. Objective: Chronic hepatitis C virus infections (HCV) cause a significant public health burden. Introduction of telaprevir (TVR) and boceprevir (BOC) has increased sustained virologic response rates (SVR) in genotype 1 patients but were accompanied by higher treatment costs and more side…

    Also available at: DOAJ